GlassScriptPhysician profile
Craig A Mcdaniel
NPI 1912960519
$6,828.10
in general payments reported to CMS, 2019-2025
47 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $611 · 2021: $1,263 · 2022: $1,292 · 2023: $1,256 · 2024: $853 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $772.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $628.77 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $616.63 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $591.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $515.63 | 2020-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $439.71 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $369.15 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $234.59 | 2021-2023 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $218.86 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Alkermes, INC. | $185.17 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Abbott Laboratories | $169.42 | 2021-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.30 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $123.59 | 2022-2025 | Auvelity |
| Lilly USA, LLC | $120.79 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $118.11 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.